Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Leukemia

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 523 articles:
HTML format
Text format



Single Articles


    February 2020
  1. ZHANG L, Li J, Xu H, Shao X, et al
    Myc-Miz-1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpalpha and Cebpdelta.
    Blood. 2020 Feb 7. pii: 441057. doi: 10.1182/blood.2019001863.
    PubMed     Text format     Abstract available


  2. PEDROSA F, Coustan-Smith E, Zhou Y, Cheng C, et al
    Reduced-dose-intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
    Blood. 2020 Feb 6. pii: 441001. doi: 10.1182/blood.2019004215.
    PubMed     Text format     Abstract available


    January 2020
  3. TISSINO E, Pozzo F, Benedetti D, Caldana C, et al
    CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
    Blood. 2020 Jan 31. pii: 440985. doi: 10.1182/blood.2019003179.
    PubMed     Text format     Abstract available


  4. MARTINO G, Ascani S
    Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia.
    Blood. 2020;135:392.
    PubMed     Text format    


  5. AL-SAWAF O, Lilienweiss E, Bahlo J, Robrecht S, et al
    High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
    Blood. 2020 Jan 27. pii: 440962. doi: 10.1182/blood.2019003451.
    PubMed     Text format    


  6. WONG R, Tan TK, Amanda S, Ngoc PCT, et al
    Feed-forward Regulatory Loop Driven by IRF4 and NF-kappaB in Adult T-cell Leukemia/Lymphoma.
    Blood. 2020 Jan 23. pii: 431345. doi: 10.1182/blood.2019002639.
    PubMed     Text format     Abstract available


  7. BEZERRA MF, Lima AS, Pique-Borras MR, Silveira DR, et al
    Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis.
    Blood. 2020 Jan 23. pii: 440480. doi: 10.1182/blood.2019003339.
    PubMed     Text format    


  8. ALDOSS I, Douer D
    How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 23. pii: 440580. doi: 10.1182/blood.2019002477.
    PubMed     Text format     Abstract available


  9. BARZ MJ, Hof J, Groeneveld-Krentz S, Loh JW, et al
    Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
    Blood. 2020 Jan 22. pii: 431280. doi: 10.1182/blood.2019002499.
    PubMed     Text format     Abstract available


  10. WOESSMANN W, Zimmermann M, Meinhardt A, Mueller S, et al
    Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy.
    Blood. 2020 Jan 21. pii: 431277. doi: 10.1182/blood.2019003591.
    PubMed     Text format     Abstract available


  11. SPYRIDONIDIS A
    How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation.
    Blood. 2020 Jan 21. pii: 431276. doi: 10.1182/blood.2019003566.
    PubMed     Text format     Abstract available


  12. HE X, Feng Z, Ma J, Ling S, et al
    Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.
    Blood. 2020 Jan 17. pii: 431045. doi: 10.1182/blood.2019002779.
    PubMed     Text format     Abstract available


  13. BLOMBERY P, Thompson E, Nguyen T, Birkinshaw RW, et al
    Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
    Blood. 2020 Jan 17. pii: 431046. doi: 10.1182/blood.2019004205.
    PubMed     Text format    


  14. ALDOSS I, Forman SJ
    How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
    PubMed     Text format     Abstract available


    December 2019
  15. FOURNIER E, Duployez N, Ducourneau B, Raffoux E, et al
    Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.
    Blood. 2019 Dec 27. pii: 430032. doi: 10.1182/blood.2019003471.
    PubMed     Text format     Abstract available


  16. BYRD JC, Wierda WG, Schuh A, Devereux S, et al
    Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Blood. 2019 Dec 26. pii: 430030. doi: 10.1182/blood.2018884940.
    PubMed     Text format     Abstract available


  17. ROBOZ GJ, DiNardo CD, Stein EM, de Botton S, et al
    Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Blood. 2019 Dec 16. pii: 429665. doi: 10.1182/blood.2019002140.
    PubMed     Text format     Abstract available


  18. DOHNER K, Thiede C, Jahn N, Panina E, et al
    Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
    Blood. 2019 Dec 11. pii: 429642. doi: 10.1182/blood.2019002697.
    PubMed     Text format     Abstract available


  19. STANULLA M, Cave H, Moorman AV
    IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
    Blood. 2019 Dec 10. pii: 429640. doi: 10.1182/blood.2019000813.
    PubMed     Text format     Abstract available


  20. SU YL, Wang X, Mann M, Adamus TP, et al
    Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo.
    Blood. 2019 Dec 5. pii: 429548. doi: 10.1182/blood.2019002045.
    PubMed     Text format     Abstract available


    November 2019
  21. DINARDO CD, Wei AH
    How I treat acute myeloid leukemia in the era of new drugs.
    Blood. 2019 Nov 25. pii: 428884. doi: 10.1182/blood.2019001239.
    PubMed     Text format     Abstract available


  22. KAY NE, Hanson CA
    B-cell prolymphocytic leukemia has 3 subsets.
    Blood. 2019;134:1777-1778.
    PubMed     Text format    


  23. TEACHEY DT, O'Connor D
    How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.
    Blood. 2019 Nov 18. pii: 428813. doi: 10.1182/blood.2019001557.
    PubMed     Text format     Abstract available


  24. CLAUDIANI S, Metelli S, Kamvar R, Szydlo R, et al
    Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  25. ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
    Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  26. TAM CS, Siddiqi T, Allan JN, Kipps TJ, et al
    Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  27. TANAKA T, Morita K, Wang F, Little L, et al
    Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  28. SHARMAN JP, Banerji V, Fogliatto LM, Herishanu Y, et al
    ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  29. STATLER A, Hobbs BP, Radivoyevitch T, Siebenaller C, et al
    The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  30. JAIN N, Keating MJ, Thompson PA, Ferrajoli A, et al
    Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  31. CIUREA SO, Varma A, Kongtim P, Srour S, et al
    Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  32. SHIMA H, Kada A, Tanizawa A, Yuza Y, et al
    Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  33. REA D, Nicolini FE, Tulliez M, Rousselot P, et al
    Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  34. LINDSLEY RC, Gibson CJ, Murdock HM, Stone RM, et al
    Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  35. SHANAFELT TD, Wang V, Kay NE, Hanson CA, et al
    Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  36. DIRAL E, Le Coutre P, Gottardi EM, Elena C, et al
    Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  37. LAMPSON BL, Tyekucheva S, Crombie JL, Kim AI, et al
    Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  38. SMITH CC, Levis MJ, Perl AE, Martinelli G, et al
    Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.
    Blood. 2019;134.
    PubMed     Text format     Abstract available


  39. RADICH J, Yeung C, Wu D
    New approaches to molecular monitoring in CML (and other diseases).
    Blood. 2019;134:1578-1584.
    PubMed     Text format     Abstract available


  40. TARUMOTO Y, Lin S, Wang J, Milazzo JP, et al
    Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
    Blood. 2019 Nov 1. pii: 422697. doi: 10.1182/blood.2019001576.
    PubMed     Text format     Abstract available


    October 2019
  41. DUPLOYEZ N, Willekens C, Plo I, Marceau-Renaut A, et al
    Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
    Blood. 2019 Oct 31. pii: 422691. doi: 10.1182/blood.2019003206.
    PubMed     Text format    


  42. SUN YM, Wang WT, Zeng ZC, Chen TQ, et al
    circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
    Blood. 2019;134:1533-1546.
    PubMed     Text format     Abstract available


  43. LI B, Brady SW, Ma X, Shen S, et al
    Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
    Blood. 2019 Oct 24. pii: 422540. doi: 10.1182/blood.2019002220.
    PubMed     Text format     Abstract available


  44. SANDERS MA
    Lifting the veil on germline DDX41 mutations.
    Blood. 2019;134:1368-1370.
    PubMed     Text format    


  45. PHILLIPS AA
    A sobering "check" on immune checkpoint inhibitors.
    Blood. 2019;134:1366-1367.
    PubMed     Text format    


  46. BURT R, Dey A, Aref S, Aguiar M, et al
    Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
    Blood. 2019;134:1415-1429.
    PubMed     Text format     Abstract available


  47. SEBERT M, Passet M, Raimbault A, Rahme R, et al
    Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
    Blood. 2019;134:1441-1444.
    PubMed     Text format     Abstract available


  48. BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
    Terminal Deoxynucleotidyl Transferase Promotes Acute Myeloid Leukemia By Priming FLT3-ITD Replication Slippage.
    Blood. 2019 Oct 17. pii: 421184. doi: 10.1182/blood.2019001238.
    PubMed     Text format     Abstract available


  49. FIELDING AK
    En-Abl-ing treatment of "Ph-like" ALL?
    Blood. 2019;134:1277-1278.
    PubMed     Text format    


  50. PATEL AB, Franzini A, Leroy E, Kim SJ, et al
    JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
    Blood. 2019 Oct 11. pii: 381160. doi: 10.1182/blood.2019001385.
    PubMed     Text format     Abstract available


  51. MUSHTAQ MU, Matson DR
    Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis.
    Blood. 2019;134:1270.
    PubMed     Text format    


  52. JIANG Y, Hu T, Wang T, Shi X, et al
    AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia.
    Blood. 2019 Oct 10. pii: 375147. doi: 10.1182/blood.2019001076.
    PubMed     Text format     Abstract available


  53. ELITZUR S, Izraeli S
    Genes driving bad luck.
    Blood. 2019;134:1199-1200.
    PubMed     Text format    


  54. RISITANO AM
    T-PLL: harmonizing criteria for research.
    Blood. 2019;134:1113-1114.
    PubMed     Text format    


  55. MORISHIMA T, Krahl AC, Nasri M, Xu Y, et al
    LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
    Blood. 2019;134:1159-1175.
    PubMed     Text format     Abstract available


    September 2019

  56. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
    Blood. 2019;134:1111.
    PubMed     Text format    


  57. SUKSWAI N, Thirabanjasak D
    B-lymphoblastic leukemia/lymphoma with an unusual appendiceal involvement.
    Blood. 2019;134:1110.
    PubMed     Text format    


  58. LUNNING M, Vose J, Nastoupil L, Fowler N, et al
    Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Blood. 2019 Sep 26. pii: blood.2019002118. doi: 10.1182/blood.2019002118.
    PubMed     Text format     Abstract available


  59. RUCKER FG, Agrawal M, Corbacioglu A, Weber D, et al
    Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.
    Blood. 2019 Sep 25. pii: blood.2019001425. doi: 10.1182/blood.2019001425.
    PubMed     Text format     Abstract available


  60. PATEL K, Danilov A, Pagel JM
    Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
    Blood. 2019 Sep 25. pii: blood.2019001795. doi: 10.1182/blood.2019001795.
    PubMed     Text format     Abstract available


  61. KHATRI SS, Kim AS
    Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma.
    Blood. 2019;134:993.
    PubMed     Text format    


  62. ASSLABER D, Qi Y, Maeding N, Steiner M, et al
    B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion.
    Blood. 2019 Sep 19. pii: blood.2019000973. doi: 10.1182/blood.2019000973.
    PubMed     Text format     Abstract available


  63. GONZALEZ-GARCIA S, Mosquera M, Fuentes P, Palumbo T, et al
    IL-7R is essential for leukemia-initiating cell activity and pathogenesis of T-cell acute lymphoblastic leukemia.
    Blood. 2019 Sep 17. pii: blood.2019000982. doi: 10.1182/blood.2019000982.
    PubMed     Text format     Abstract available


  64. CHAPIRO E, Pramil E, Diop M, Roos-Weil D, et al
    Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
    Blood. 2019 Sep 16. pii: blood.2019001187. doi: 10.1182/blood.2019001187.
    PubMed     Text format     Abstract available


  65. JULIUSSON G, Hagberg O, Lazarevic VL, Olander E, et al
    Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.
    Blood. 2019 Sep 12. pii: blood.2019001728. doi: 10.1182/blood.2019001728.
    PubMed     Text format    


  66. PARK CS, Lewis AH, Chen TJ, Bridges CS, et al
    KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.
    Blood. 2019 Sep 12. pii: blood.2018875922. doi: 10.1182/blood.2018875922.
    PubMed     Text format     Abstract available


  67. HASSERJIAN RP
    Illuminating neutrophilic myeloid neoplasms.
    Blood. 2019;134:846-848.
    PubMed     Text format    


  68. TAM CS, Trotman J, Opat S, Burger JA, et al
    Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
    Blood. 2019;134:851-859.
    PubMed     Text format     Abstract available


  69. BATTIPAGLIA G, Labopin M, Kroger N, Vitek A, et al
    Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
    Blood. 2019;134:892-899.
    PubMed     Text format     Abstract available


  70. BUENO C, Tejedor JR, Bashford-Rogers R, Gonzalez-Silva L, et al
    Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL.
    Blood. 2019;134:900-905.
    PubMed     Text format    


  71. HIJIYA N, Maschan A, Rizzari C, Shimada H, et al
    Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
    Blood. 2019 Sep 11. pii: blood.2019000069. doi: 10.1182/blood.2019000069.
    PubMed     Text format     Abstract available


  72. BROUX M, Prieto C, Demeyer S, Vanden Bempt M, et al
    Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
    Blood. 2019 Sep 6. pii: blood.2019000015. doi: 10.1182/blood.2019000015.
    PubMed     Text format     Abstract available


  73. STEPHENS DM
    Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia.
    Blood. 2019 Sep 5. pii: blood.2019001750. doi: 10.1182/blood.2019001750.
    PubMed     Text format     Abstract available


    August 2019
  74. LEFEBVRE T, Mauvieux L
    A gelatinous leukemia.
    Blood. 2019;134:785.
    PubMed     Text format    


  75. RAUCH DA, Conlon KC, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade.
    Blood. 2019 Aug 29. pii: blood.2019002038. doi: 10.1182/blood.2019002038.
    PubMed     Text format     Abstract available


  76. PERL AE
    Availability of FLT3 inhibitors: how do we use them?
    Blood. 2019;134:741-745.
    PubMed     Text format     Abstract available



  77. Steele AJ, Prentice AG, Hoffbrand AV, et al. 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood. 2009;114(6):1217-1225.
    Blood. 2019;134:719-721.
    PubMed     Text format    


  78. WANG HY, Hinds BR
    Cutaneous composite small lymphocytic lymphoma and primary cutaneous follicle center lymphoma.
    Blood. 2019;134:717.
    PubMed     Text format    


  79. TANASI I, Ba I, Sirvent N, Braun T, et al
    Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements.
    Blood. 2019 Aug 21. pii: blood.2019001244. doi: 10.1182/blood.2019001244.
    PubMed     Text format    



  80. Oral arsenic for acute promyelocytic leukemia.
    Blood. 2019;134:659.
    PubMed     Text format    


  81. QUINQUENEL A, Fornecker LM, Letestu R, Ysebaert L, et al
    Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
    Blood. 2019;134:641-644.
    PubMed     Text format     Abstract available


  82. JANKE LJ, Van Driest SL, Portera MV, Atreya RV, et al
    Hypertension is a modifiable risk-factor for osteonecrosis in acute lymphoblastic leukemia.
    Blood. 2019 Aug 13. pii: blood.2019000006. doi: 10.1182/blood.2019000006.
    PubMed     Text format    


  83. CHEN Y, Chen L, Yu J, Ghia EM, et al
    Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-kappaB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia.
    Blood. 2019 Aug 13. pii: blood.2019001366. doi: 10.1182/blood.2019001366.
    PubMed     Text format     Abstract available


  84. ZHU Y, He X, Lin YC, Dong H, et al
    Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.
    Blood. 2019 Aug 8. pii: blood.2019002457. doi: 10.1182/blood.2019002457.
    PubMed     Text format     Abstract available


  85. VENDITTI A, Piciocchi A, Candoni A, Melillo L, et al
    GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.
    Blood. 2019 Aug 8. pii: blood.2018886960. doi: 10.1182/blood.2018886960.
    PubMed     Text format     Abstract available


  86. GRITSMAN K
    FLT3-ITD gets by with a little help from PRMT1.
    Blood. 2019;134:498-500.
    PubMed     Text format    


  87. KLEIN U
    Resolving PI3K-delta inhibitor resistance in CLL.
    Blood. 2019;134:496-498.
    PubMed     Text format    


  88. COFFY S, Shi M
    Giant intracytoplasmic inclusions in a T-cell large granular lymphocytic leukemia patient with acute severe anemia.
    Blood. 2019;134:492.
    PubMed     Text format    


  89. CHIANG CL, Goswami S, Frissora FW, Xie Z, et al
    ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
    Blood. 2019;134:432-444.
    PubMed     Text format     Abstract available


    July 2019
  90. BROWN AL, de Smith AJ, Gant VU, Yang W, et al
    Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome.
    Blood. 2019 Jul 26. pii: blood.2018890764. doi: 10.1182/blood.2018890764.
    PubMed     Text format     Abstract available


  91. HERMANS SJF, Sandberg Y
    T-cell prolymphocytic leukemia presenting as ascites.
    Blood. 2019;134:411.
    PubMed     Text format    


  92. STUANI L, Sarry JE
    Help from outside: cysteine to survive in AML.
    Blood. 2019;134:336-338.
    PubMed     Text format    


  93. VASSILIOU GS
    Triple-mutant AML: too clever by HLF?
    Blood. 2019;134:222-224.
    PubMed     Text format    


  94. CHIANG MY
    Finding ARIEL under the sea of T-ALL circuits.
    Blood. 2019;134:219-221.
    PubMed     Text format    


  95. LI W, Cooley LD, August KJ, Richardson AI, et al
    Cuplike nuclear morphology is highly associated with IKZF1 deletion in pediatric precursor B-cell ALL.
    Blood. 2019;134:324-329.
    PubMed     Text format    


  96. GOCHO Y, Yang JJ
    Genetic Defects in Hematopoietic Transcription Factors and Predisposition to Acute Lymphoblastic Leukemia.
    Blood. 2019 Jul 16. pii: blood.2018852400. doi: 10.1182/blood.2018852400.
    PubMed     Text format     Abstract available


  97. VOGIATZI F, Winterberg D, Lenk L, Buchmann S, et al
    Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2019 Jul 16. pii: blood.2019000904. doi: 10.1182/blood.2019000904.
    PubMed     Text format    


  98. ROSSI D
    Quest of biomarkers for venetoclax-treated CLL.
    Blood. 2019;134:97-98.
    PubMed     Text format    


  99. STABER PB, Herling M, Bellido M, Jacobsen ED, et al
    Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).
    Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402.
    PubMed     Text format     Abstract available


  100. GIACOPELLI B, Zhao Q, Ruppert AS, Agyeman A, et al
    Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.
    Blood. 2019 Jul 10. pii: blood.2019000490. doi: 10.1182/blood.2019000490.
    PubMed     Text format     Abstract available


  101. LUCENA-ARAUJO AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR MD, et al
    Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.
    Blood. 2019 Jul 10. pii: blood.2019000239. doi: 10.1182/blood.2019000239.
    PubMed     Text format     Abstract available



  102. Nguyen TD, Shaid S, Vakhrusheva O, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. Blood. 2019;133(2):168-179.
    Blood. 2019;134:94.
    PubMed     Text format    


  103. MILL CP, Fiskus W, DiNardo CD, Qian Y, et al
    RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
    Blood. 2019;134:59-73.
    PubMed     Text format     Abstract available


  104. SHANMUGANATHAN N, Braley JA, Yong ASM, Hiwase DK, et al
    Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.
    Blood. 2019;134:85-89.
    PubMed     Text format    


  105. HU T, Morita K, Hill MC, Jiang Y, et al
    PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells.
    Blood. 2019 Jul 3. pii: blood.2018888255. doi: 10.1182/blood.2018888255.
    PubMed     Text format     Abstract available


    June 2019
  106. DI PAOLA J, Porter CC
    ETV6-Related Thrombocytopenia and Leukemia Predisposition.
    Blood. 2019 Jun 27. pii: blood.2019852418. doi: 10.1182/blood.2019852418.
    PubMed     Text format     Abstract available


  107. COUTRE S
    A one-two punch with VO KOs CLL.
    Blood. 2019;133:2737-2738.
    PubMed     Text format    


  108. ROTUNNO G, Mannarelli C, Brogi G, Pacilli A, et al
    Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.
    Blood. 2019;133:2802-2808.
    PubMed     Text format    


  109. GODLEY LA
    FouNdER mutations confer risk for leukemias.
    Blood. 2019;133:2636-2638.
    PubMed     Text format    


  110. HEUSER M, Lai CK
    Message from the void: MRD analysis from ctDNA.
    Blood. 2019;133:2631-2633.
    PubMed     Text format    


  111. CHIODIN G, Forconi F
    Hedgehog activation in CLL.
    Blood. 2019;133:2628-2630.
    PubMed     Text format    


  112. HE X, Zhu Y, Lin YC, Li M, et al
    PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) Acute Myeloid Leukemia.
    Blood. 2019 Jun 19. pii: blood.2019001282. doi: 10.1182/blood.2019001282.
    PubMed     Text format     Abstract available



  113. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.
    Blood. 2019;133:2625.
    PubMed     Text format    


  114. KWON R, Duffield AS
    HTLV-1-associated adult T-cell leukemia/lymphoma with disseminated strongyloidiasis.
    Blood. 2019;133:2623.
    PubMed     Text format    


  115. YOSHIMOTO M
    B-1 progenitor acute lymphoid leukemia.
    Blood. 2019;133:2557-2558.
    PubMed     Text format    


  116. RUDORF A, Muller TA, Klingeberg C, Kreutmair S, et al
    NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.
    Blood. 2019 Jun 11. pii: blood.2018883140. doi: 10.1182/blood.2018883140.
    PubMed     Text format     Abstract available


    May 2019
  117. AHN IE, Basumallik N, Tian X, Soto S, et al
    Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
    Blood. 2019;133:2452-2455.
    PubMed     Text format    


  118. EDITORIAL OFFICE B
    RETRACTION: Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006
    Blood. 2019 May 24. pii: blood-2019-05-901215. doi: 10.1182/blood-2019-05-901215
    PubMed     Text format    


  119. SYKES SM
    NCAM1 supports therapy resistance and LSC function in AML.
    Blood. 2019;133:2247-2248.
    PubMed     Text format    


  120. MACIOCIA PM, Pule MA
    Anti-CD1a CAR T cells to selectively target T-ALL.
    Blood. 2019;133:2246-2247.
    PubMed     Text format    


  121. DIECK CL, Ferrando A
    Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
    Blood. 2019;133:2263-2268.
    PubMed     Text format     Abstract available


  122. SASCA D, Szybinski J, Schuler A, Shah V, et al
    NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
    Blood. 2019;133:2305-2319.
    PubMed     Text format     Abstract available


  123. ZHU HH, Hu J, Lo Coco F, Jin J, et al
    The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.
    Blood. 2019 May 21. pii: blood.2019000760. doi: 10.1182/blood.2019000760.
    PubMed     Text format     Abstract available


  124. JONES CL, Stevens BM, D'Alessandro A, Culp-Hill R, et al
    Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.
    Blood. 2019 May 17. pii: blood.2019898114. doi: 10.1182/blood.2019898114.
    PubMed     Text format     Abstract available


  125. YANG J, Gabali A
    Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome.
    Blood. 2019;133:2243.
    PubMed     Text format    


  126. MAGGI M, Scotti C
    HAP1 loss in l-asparaginase resistance.
    Blood. 2019;133:2116-2118.
    PubMed     Text format    


  127. LEE JK, Kang S, Wang X, Rosales JL, et al
    HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.
    Blood. 2019;133:2222-2232.
    PubMed     Text format     Abstract available


  128. KARSCHNIA P, Jordan JT, Forst DA, Arrillaga-Romany IC, et al
    Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
    Blood. 2019;133:2212-2221.
    PubMed     Text format     Abstract available


  129. VAN BRUGGEN JAC, Martens AWJ, Fraietta JA, Hofland T, et al
    Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.
    Blood. 2019 May 10. pii: blood.2018885863. doi: 10.1182/blood.2018885863.
    PubMed     Text format     Abstract available


  130. GARG S, Reyes-Palomares A, He L, Bergeron A, et al
    Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
    Blood. 2019 May 10. pii: blood.2018862383. doi: 10.1182/blood.2018862383.
    PubMed     Text format     Abstract available


  131. TAN SH, Leong WZ, Ngoc PCT, Tan TK, et al
    The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.
    Blood. 2019 May 10. pii: blood.2018874503. doi: 10.1182/blood.2018874503.
    PubMed     Text format     Abstract available


  132. SLUPSKY JR
    Ibrutinib is safer than we think.
    Blood. 2019;133:2006-2007.
    PubMed     Text format    


  133. WENDTNER CM
    Ibrutinib: the home run for cure in CLL?
    Blood. 2019;133:2003-2004.
    PubMed     Text format    


  134. BYRD JC, Hillmen P, O'Brien S, Barrientos JC, et al
    Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood. 2019;133:2031-2042.
    PubMed     Text format     Abstract available


    April 2019
  135. DERRIEUX C, Tarfi S
    Azurophilic granular blasts are not always part of myeloid lineage: an atypical case of BCP acute lymphoblastic leukemia.
    Blood. 2019;133:1919.
    PubMed     Text format    


  136. BJORKHOLM M, Edgren G, Dickman PW
    Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and USA.
    Blood. 2019 Apr 25. pii: blood.2019001168. doi: 10.1182/blood.2019001168.
    PubMed     Text format    


  137. ROBERTS AW, Ma S, Kipps TJ, Coutre SE, et al
    Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
    Blood. 2019 Apr 25. pii: blood.2018882555. doi: 10.1182/blood.2018882555.
    PubMed     Text format     Abstract available


  138. SCHEFFOLD A, Jebaraj BMC, Tausch E, Bloehdorn J, et al
    IGF1R as druggable target mediating PI3K-delta inhibitor resistance in a murine model of chronic lymphocytic leukemia.
    Blood. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029.
    PubMed     Text format     Abstract available


  139. PLESA A, Sujobert P
    Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.
    Blood. 2019;133:1789.
    PubMed     Text format    


  140. TROWBRIDGE JJ
    Context-specific tumor suppression by PHF6.
    Blood. 2019;133:1698-1700.
    PubMed     Text format    


  141. FORERO-TORRES A, Ramchandren R, Yacoub A, Wertheim MS, et al
    Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies.
    Blood. 2019;133:1742-1752.
    PubMed     Text format     Abstract available


  142. CURRAN E, Stock W
    Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
    Blood. 2019;133:1715-1719.
    PubMed     Text format     Abstract available


  143. JUTZI JS, Basu T, Pellmann M, Kaiser S, et al
    Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
    Blood. 2019;133:1766-1777.
    PubMed     Text format     Abstract available


  144. YIN M, Chung YJ, Lindsley RC, Walker RL, et al
    Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.
    Blood. 2019 Apr 16. pii: blood.2018864173. doi: 10.1182/blood.2018864173.
    PubMed     Text format     Abstract available


  145. ZHAN Y, Teruya-Feldstein J
    Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL.
    Blood. 2019;133:1695.
    PubMed     Text format    


  146. HAY KA, Gauthier J, Hirayama AV, Voutsinas JM, et al
    Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Blood. 2019;133:1652-1663.
    PubMed     Text format     Abstract available


  147. DOUGLAS SPM, Siipola P, Kovanen P, Pyorala M, et al
    ERCC6L2 defines a novel entity within inherited acute myeloid leukemia.
    Blood. 2019 Apr 1. pii: blood-2019-01-896233. doi: 10.1182/blood-2019-01-896233.
    PubMed     Text format    


  148. NAKAMURA S, Yokoyama K, Shimizu E, Yusa N, et al
    Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
    Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690.
    PubMed     Text format     Abstract available


    March 2019
  149. GHIA EM, Rassenti LZ, Neuberg DS, Blanco A, et al
    Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.
    Blood. 2019 Mar 28. pii: blood-2018-09-873695. doi: 10.1182/blood-2018-09-873695
    PubMed     Text format     Abstract available


  150. LEVIS M
    Arsenic and old FLT3.
    Blood. 2019;133:1392-1393.
    PubMed     Text format    


  151. WEI AH
    Maintenance therapy for AML: are we there yet?
    Blood. 2019;133:1390-1392.
    PubMed     Text format    


  152. GOHIL SH, Wu CJ
    Dissecting CLL through high-dimensional single-cell technologies.
    Blood. 2019;133:1446-1456.
    PubMed     Text format     Abstract available


  153. ESNAULT C, Rahme R, Rice KL, Berthier C, et al
    FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
    Blood. 2019;133:1495-1506.
    PubMed     Text format     Abstract available


  154. GOLAY J, Valgardsdottir R, Musaraj G, Giupponi D, et al
    Human neutrophils express low levels of FcgammaRIIIA, which plays a role in PMN activation.
    Blood. 2019;133:1395-1405.
    PubMed     Text format     Abstract available


  155. HULS G, Chitu DA, Havelange V, Jongen-Lavrencic M, et al
    Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
    Blood. 2019;133:1457-1464.
    PubMed     Text format     Abstract available


  156. HIJIYA N, Suttorp M
    How I Treat Chronic Myeloid Leukemia in Children and Adolescents.
    Blood. 2019 Mar 27. pii: blood.2018882233. doi: 10.1182/blood.2018882233.
    PubMed     Text format     Abstract available


  157. SARASIN A, Quentin S, Droin N, Sahbatou M, et al
    Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.
    Blood. 2019 Mar 26. pii: blood-2019-01-895698. doi: 10.1182/blood-2019-01-895698
    PubMed     Text format    


  158. CARGO C, Cullen M, Taylor J, Short M, et al
    The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
    Blood. 2019;133:1325-1334.
    PubMed     Text format     Abstract available


  159. ZEISER R, Vago L
    Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.
    Blood. 2019;133:1290-1297.
    PubMed     Text format     Abstract available


  160. LIU H
    Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged.
    Blood. 2019;133:1265.
    PubMed     Text format    


  161. FRANCISCHETTI IMB, Calvo KR
    Hairy cell leukemia coexistent with chronic lymphocytic leukemia.
    Blood. 2019;133:1264.
    PubMed     Text format    


  162. ABRUZZO LV
    Intricacies of CLL cytogenetic complexity.
    Blood. 2019;133:1168-1170.
    PubMed     Text format    


  163. BORDEN KLB
    CDK9 and mTOR: trading places.
    Blood. 2019;133:1167-1168.
    PubMed     Text format    


  164. FLINN IW, Gribben JG, Dyer MJS, Wierda W, et al
    Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Blood. 2019 Mar 12. pii: blood-2019-01-896290. doi: 10.1182/blood-2019-01-896290
    PubMed     Text format     Abstract available


  165. HAFERLACH T, Meggendorfer M
    More than a fusion gene: the RUNX1-RUNX1T1 AML.
    Blood. 2019;133:1006-1007.
    PubMed     Text format    


  166. BYRD JC
    Targeting CD20 takes the backseat in CLL.
    Blood. 2019;133:1003-1004.
    PubMed     Text format    


  167. MERKENSCHLAGER J, Eksmond U, Danelli L, Attig J, et al
    MHC class II cell-autonomously regulates self-renewal and differentiation of normal and malignant B cells.
    Blood. 2019;133:1108-1118.
    PubMed     Text format     Abstract available


  168. PRONK E, Raaijmakers MHGP
    The mesenchymal niche in MDS.
    Blood. 2019;133:1031-1038.
    PubMed     Text format     Abstract available


  169. TANAKA TN, Bejar R
    MDS overlap disorders and diagnostic boundaries.
    Blood. 2019;133:1086-1095.
    PubMed     Text format     Abstract available


  170. OGAWA S
    Genetics of MDS.
    Blood. 2019;133:1049-1059.
    PubMed     Text format     Abstract available


    February 2019
  171. BROWN JR, O'Brien S, Kingsley CD, Eradat H, et al
    Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
    Blood. 2019;133:990-992.
    PubMed     Text format    


  172. MORANDE PE, Sivina M, Uriepero A, Seija N, et al
    Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Blood. 2019 Feb 27. pii: blood-2018-09-876292. doi: 10.1182/blood-2018-09-876292
    PubMed     Text format     Abstract available


  173. SANZ MA, Fenaux P, Tallman MS, Estey EH, et al
    Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
    Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980
    PubMed     Text format     Abstract available


  174. KAUFMANN KB, Garcia-Prat L, Liu Q, Ng SWK, et al
    A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
    Blood. 2019 Feb 22. pii: blood-2018-10-881441. doi: 10.1182/blood-2018-10-881441
    PubMed     Text format     Abstract available


  175. SANCHEZ-MARTINEZ D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H, et al
    Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
    Blood. 2019 Feb 22. pii: blood-2018-10-882944. doi: 10.1182/blood-2018-10-882944
    PubMed     Text format     Abstract available


  176. ROSSI D
    FBXW7 is a biologically validated cancer driver gene for CLL.
    Blood. 2019;133:774-776.
    PubMed     Text format    


  177. CLOSE V, Close W, Kugler SJ, Reichenzeller M, et al
    FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.
    Blood. 2019;133:830-839.
    PubMed     Text format     Abstract available


  178. SCHMIEGELOW K
    Yet another susceptibility variant for ALL: what's next?
    Blood. 2019;133:628-629.
    PubMed     Text format    


  179. BULLINGER L
    IDH2 inhibition: another piece to the puzzle.
    Blood. 2019;133:625-626.
    PubMed     Text format    


  180. STERNER RM, Sakemura R, Cox MJ, Yang N, et al
    GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
    Blood. 2019;133:697-709.
    PubMed     Text format     Abstract available


  181. MCRAE HM, Garnham AL, Hu Y, Witkowski MT, et al
    PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.
    Blood. 2019 Feb 12. pii: blood-2018-07-860726. doi: 10.1182/blood-2018-07-860726
    PubMed     Text format     Abstract available


  182. SMITH CC
    Roman warfare: targeting of support cells in AML.
    Blood. 2019;133:506-507.
    PubMed     Text format    


    January 2019
  183. STEPHENS DM
    Highs and lows of minimal residual disease in CLL.
    Blood. 2019;133:386-388.
    PubMed     Text format    


  184. LANGERAK AW, Ritgen M, Goede V, Robrecht S, et al
    Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
    Blood. 2019;133:494-497.
    PubMed     Text format    


  185. NIEMEYER CM, Flotho C
    Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Blood. 2019 Jan 22. pii: blood-2018-11-844688. doi: 10.1182/blood-2018-11-844688
    PubMed     Text format     Abstract available


  186. STOCK W, Luger SM, Advani AS, Yin J, et al
    A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
    Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961
    PubMed     Text format     Abstract available


  187. HALLNER A, Bernson E, Hussein BA, Sander FE, et al
    The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
    Blood. 2019 Jan 15. pii: blood-2018-09-874990. doi: 10.1182/blood-2018-09-874990
    PubMed     Text format     Abstract available


  188. STEPHENS DM, Byrd JC
    How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
    Blood. 2019 Jan 14. pii: blood-2018-11-846808. doi: 10.1182/blood-2018-11-846808
    PubMed     Text format     Abstract available


  189. XIE W, Xu J
    Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia.
    Blood. 2019;133:182.
    PubMed     Text format    


  190. TORUNER GA, Thakral B
    Relapsed NPM1 mutated acute myeloid leukemia with PDGFRA rearrangement.
    Blood. 2019;133:181.
    PubMed     Text format    


  191. SARRAF YAZDY M, Mato AR, Cheson BD
    Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
    Blood. 2019;133:121-129.
    PubMed     Text format     Abstract available


  192. CHRISTEN F, Hoyer K, Yoshida K, Hou HA, et al
    Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
    Blood. 2019 Jan 4. pii: blood-2018-05-852822. doi: 10.1182/blood-2018-05-852822.
    PubMed     Text format     Abstract available


  193. MICHAELIS LC
    Venetoclax in AML: aiming for "just right".
    Blood. 2019;133:3-4.
    PubMed     Text format    


  194. BALIAKAS P, Jeromin S, Iskas M, Puiggros A, et al
    Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact.
    Blood. 2019 Jan 2. pii: blood-2018-09-873083. doi: 10.1182/blood-2018-09-873083.
    PubMed     Text format     Abstract available


    December 2018
  195. BEAUCHAMP EM, Abedin SM, Radecki SG, Fischietti M, et al
    Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
    Blood. 2018 Dec 26. pii: blood-2018-08-870089. doi: 10.1182/blood-2018-08-870089
    PubMed     Text format     Abstract available


  196. SCHLENK RF, Weber D, Fiedler W, Salih HR, et al
    Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
    Blood. 2018 Dec 18. pii: blood-2018-08-869453. doi: 10.1182/blood-2018-08-869453
    PubMed     Text format     Abstract available


  197. BILICH T, Nelde A, Bichmann L, Roerden M, et al
    The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Blood. 2018 Dec 10. pii: blood-2018-07-866830. doi: 10.1182/blood-2018-07-866830
    PubMed     Text format     Abstract available


  198. BURGER JA, Sivina M, Jain N, Kim E, et al
    Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Blood. 2018 Dec 7. pii: blood-2018-10-879429. doi: 10.1182/blood-2018-10-879429.
    PubMed     Text format     Abstract available


  199. PASSET M, Boissel N, Sigaux F, Saillard C, et al
    PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.
    Blood. 2018 Dec 3. pii: blood-2018-10-882142. doi: 10.1182/blood-2018-10-882142.
    PubMed     Text format    


  200. QIAN M, Xu H, Perez-Andreu V, Roberts KG, et al
    Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics.
    Blood. 2018 Dec 3. pii: blood-2018-07-862946. doi: 10.1182/blood-2018-07-862946.
    PubMed     Text format     Abstract available


  201. STEIN EM, DiNardo CD, Fathi AT, Pollyea DA, et al
    Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
    Blood. 2018 Dec 3. pii: blood-2018-08-869008. doi: 10.1182/blood-2018-08-869008.
    PubMed     Text format     Abstract available


    November 2018
  202. KLAIRMONT MM, Choi JK
    Mixed-phenotype acute leukemia, T/megakaryoblastic.
    Blood. 2018;132:2418.
    PubMed     Text format    


  203. NGUYEN TD, Shaid S, Vakhrusheva O, Koschade SE, et al
    Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.
    Blood. 2018 Nov 29. pii: blood-2018-02-833475. doi: 10.1182/blood-2018-02-833475
    PubMed     Text format     Abstract available


  204. JIANG W, Lee SH
    Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
    Blood. 2018;132:2314.
    PubMed     Text format    


  205. BROWN P, Pieters R, Biondi A
    How I treat infant leukemia.
    Blood. 2018 Nov 20. pii: blood-2018-04-785980. doi: 10.1182/blood-2018-04-785980
    PubMed     Text format     Abstract available


  206. RAVANDI F
    How I treat Philadelphia chromosome positive acute lymphoblastic leukemia.
    Blood. 2018 Nov 15. pii: blood-2018-08-832105. doi: 10.1182/blood-2018-08-832105
    PubMed     Text format     Abstract available


  207. EDWARDS DK 5TH, Watanabe-Smith K, Rofelty A, Damnernsawad A, et al
    CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
    Blood. 2018 Nov 13. pii: blood-2018-03-838946. doi: 10.1182/blood-2018-03-838946
    PubMed     Text format     Abstract available


  208. LEBECQUE B, Lechevalier N
    B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia.
    Blood. 2018;132:2107.
    PubMed     Text format    


  209. ABDUL-AZIZ AM, Sun Y, Hellmich C, Marlein CR, et al
    Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment.
    Blood. 2018 Nov 6. pii: blood-2018-04-845420. doi: 10.1182/blood-2018-04-845420.
    PubMed     Text format     Abstract available


    October 2018
  210. DINARDO CD, Pratz K, Pullarkat V, Jonas BA, et al
    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    Blood. 2018 Oct 25. pii: blood-2018-08-868752. doi: 10.1182/blood-2018-08-868752
    PubMed     Text format     Abstract available


  211. BERTAINA A, Zecca M, Buldini B, Sacchi N, et al
    Unrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemia.
    Blood. 2018 Oct 22. pii: blood-2018-07-861575. doi: 10.1182/blood-2018-07-861575
    PubMed     Text format     Abstract available


  212. ZHANG J, Zhang Y, Zhang M, Liu C, et al
    FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia.
    Blood. 2018 Oct 3. pii: blood-2018-04-845628. doi: 10.1182/blood-2018-04-845628.
    PubMed     Text format    


  213. HERRMANN M, Krupka C, Deiser K, Brauchle B, et al
    Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Blood. 2018 Oct 1. pii: blood-2018-05-849802. doi: 10.1182/blood-2018-05-849802.
    PubMed     Text format     Abstract available


    September 2018
  214. CHEN LS, Bose P, Cruz ND, Jiang Y, et al
    A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Blood. 2018 Sep 25. pii: blood-2018-06-860593. doi: 10.1182/blood-2018-06-860593
    PubMed     Text format     Abstract available


  215. BALATTI V, Tomasello L, Rassenti LZ, Veneziano D, et al
    MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
    Blood. 2018 Sep 21. pii: blood-2018-04-845115. doi: 10.1182/blood-2018-04-845115
    PubMed     Text format     Abstract available


  216. BOSMA M, Bartels M
    Hairy cell leukemia in a child?!
    Blood. 2018;132:1216.
    PubMed     Text format    


  217. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.
    PubMed     Text format    


  218. BRETONES G, Alvarez MG, Arango JR, Rodriguez D, et al
    Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.
    Blood. 2018 Sep 4. pii: blood-2017-09-804401. doi: 10.1182/blood-2017-09-804401.
    PubMed     Text format     Abstract available


    August 2018
  219. ALSADEQ A, Lenk L, Vadakumchery A, Cousins A, et al
    IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Aug 28. pii: blood-2018-04-844209. doi: 10.1182/blood-2018-04-844209
    PubMed     Text format    


  220. MEDEIROS BC
    Non-zero-sum game of transfusions: EOL in leukemia.
    Blood. 2018;132:676-678.
    PubMed     Text format    


  221. ROGERS KA, Huang Y, Ruppert AS, Awan FT, et al
    Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Blood. 2018 Aug 15. pii: blood-2018-05-853564. doi: 10.1182/blood-2018-05-853564
    PubMed     Text format     Abstract available


  222. KIM T, Moon JH, Ahn JS, Kim YK, et al
    Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia.
    Blood. 2018 Aug 14. pii: blood-2018-04-848028. doi: 10.1182/blood-2018-04-848028
    PubMed     Text format     Abstract available


  223. FERGUSON D, Kovach AE
    Rasburicase-induced hemolytic anemia in previously undiagnosed G6PD deficiency.
    Blood. 2018;132:673.
    PubMed     Text format    


    July 2018
  224. PIKMAN Y, Stegmaier K
    Targeted therapy for fusion-driven high-risk acute leukemia.
    Blood. 2018 Jul 26. pii: blood-2018-04-784157. doi: 10.1182/blood-2018-04-784157
    PubMed     Text format     Abstract available


  225. RICHARDSON AI, Li W
    Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia.
    Blood. 2018;132:457.
    PubMed     Text format    


  226. LI W, Chastain K
    NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia.
    Blood. 2018;132:456.
    PubMed     Text format    



  227. Ambiguous lineage leukemia treatment.
    Blood. 2018;132:343.
    PubMed     Text format    


  228. DREGER P, Ghia P, Schetelig J, van Gelder M, et al
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
    Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008
    PubMed     Text format     Abstract available


  229. SUD A, Chattopadhyay S, Thomsen H, Sundquist K, et al
    Familial risks of primary myeloid leukemia, myelodysplasia and myeloproliferative neoplasms.
    Blood. 2018 Jul 10. pii: blood-2018-06-858597. doi: 10.1182/blood-2018-06-858597
    PubMed     Text format    


  230. THAKRAL B, Wang SA
    T-cell prolymphocytic leukemia negative for surface CD3 and CD45.
    Blood. 2018;132:111.
    PubMed     Text format    


    June 2018
  231. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991
    PubMed     Text format    


  232. O'DWYER K, Freyer DR, Horan JT
    Treatment strategies for adolescent and young adult patients with acute myeloid leukemia.
    Blood. 2018 Jun 12. pii: blood-2017-12-778472. doi: 10.1182/blood-2017-12-778472
    PubMed     Text format     Abstract available


  233. BOISSEL N, Baruchel A
    Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
    Blood. 2018 Jun 12. pii: blood-2018-02-778530. doi: 10.1182/blood-2018-02-778530
    PubMed     Text format     Abstract available


  234. ROBERTS KG, Janke LJ, Zhao Y, Seth A, et al
    ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
    Blood. 2018 Jun 7. pii: blood-2018-05-849554. doi: 10.1182/blood-2018-05-849554.
    PubMed     Text format    


    May 2018
  235. ALDOSS I, Song JY
    Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.
    Blood. 2018;131:2507.
    PubMed     Text format    


  236. LEBLANC TW, Egan PC, Olszewski AJ
    Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.
    Blood. 2018 May 30. pii: blood-2018-03-842575. doi: 10.1182/blood-2018-03-842575
    PubMed     Text format     Abstract available


  237. MELO-CARDENAS J, Xu Y, Wei J, Tan C, et al
    USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism.
    Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760
    PubMed     Text format     Abstract available


  238. PATEL SS, Dorfman DM
    Leukemic-phase progression of aleukemic mast cell leukemia.
    Blood. 2018;131:2406.
    PubMed     Text format    


  239. TESTI AM, Pession A, Diverio D, Grimwade D, et al
    Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.
    Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528
    PubMed     Text format     Abstract available


  240. MAIFREDE S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895. doi: 10.1182/blood-2018-02-834895
    PubMed     Text format     Abstract available


  241. CLOT G, Jares P, Gine E, Navarro A, et al
    A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
    Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
    PubMed     Text format     Abstract available


  242. LUO H, Wang F, Zha J, Li H, et al
    CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
    Blood. 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319
    PubMed     Text format     Abstract available


  243. OLAIYA OO, Li W
    Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia.
    Blood. 2018;131:2178.
    PubMed     Text format    


  244. ROBINSON HR, Qi J, Cook EM, Nichols C, et al
    A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Blood. 2018 May 9. pii: blood-2018-02-830992. doi: 10.1182/blood-2018-02-830992.
    PubMed     Text format     Abstract available


  245. TOPP MS, Zimmerman Z, Cannell P, Dombret H, et al
    Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Blood. 2018 May 8. pii: blood-2017-09-804658. doi: 10.1182/blood-2017-09-804658.
    PubMed     Text format     Abstract available


  246. ZHU HH, Liu YR
    Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia.
    Blood. 2018 May 4. pii: blood-2018-02-834051. doi: 10.1182/blood-2018-02-834051.
    PubMed     Text format    


  247. STEIN EM, Garcia-Manero G, Rizzieri DA, Tibes R, et al
    The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Blood. 2018 May 3. pii: blood-2017-12-818948. doi: 10.1182/blood-2017-12-818948.
    PubMed     Text format     Abstract available


  248. HRUSAK O, De Haas V, Stancikova J, Vakrmanova B, et al
    International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
    Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363.
    PubMed     Text format     Abstract available


    April 2018
  249. LI S, Xu J
    Plasma cell leukemia presenting as "lymphocytosis".
    Blood. 2018;131:1994.
    PubMed     Text format    


  250. YANG J, LeBlanc FR, Dighe SA, Hamele CE, et al
    TRAIL mediates and sustains constitutive NF-kappaB activation in LGL leukemia.
    Blood. 2018 Apr 26. pii: blood-2017-09-808816. doi: 10.1182/blood-2017-09-808816
    PubMed     Text format     Abstract available


  251. MCKENNA MK, Noothi SK, Alhakeem SS, Oben KZ, et al
    Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    Blood. 2018 Apr 25. pii: blood-2017-10-813931. doi: 10.1182/blood-2017-10-813931
    PubMed     Text format     Abstract available


  252. ITZYKSON R, Duployez N, Fasan A, Decool G, et al
    Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.
    Blood. 2018 Apr 24. pii: blood-2018-03-837781. doi: 10.1182/blood-2018-03-837781
    PubMed     Text format     Abstract available


  253. HASAN MK, Yu J, Widhopf GF 2nd, Rassenti LZ, et al
    Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Blood. 2018 Apr 20. pii: blood-2017-12-819383. doi: 10.1182/blood-2017-12-819383
    PubMed     Text format     Abstract available


  254. KLEINSTERN G, Camp NJ, Goldin LR, Vachon CM, et al
    Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
    Blood. 2018 Apr 19. pii: blood-2017-11-814608. doi: 10.1182/blood-2017-11-814608
    PubMed     Text format     Abstract available


  255. HEERY DM
    A fellowship of Ring1 maintains AML stem cells.
    Blood. 2018;131:1771-1773.
    PubMed     Text format    


  256. LAETSCH TW, Maude SL, Milone MC, Davis KL, et al
    False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
    Blood. 2018 Apr 18. pii: blood-2017-12-822940. doi: 10.1182/blood-2017-12-822940
    PubMed     Text format    


  257. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Text format     Abstract available


  258. RANK CU, Toft N, Tuckuviene R, Grell K, et al
    Thromboembolism in Acute Lymphoblastic Leukemia: Results of NOPHO ALL2008 Protocol Treatment in Patients 1-45 Years.
    Blood. 2018 Apr 16. pii: blood-2018-01-827949. doi: 10.1182/blood-2018-01-827949
    PubMed     Text format     Abstract available


  259. JIANG X, Zhou D
    ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
    Blood. 2018;131:1764.
    PubMed     Text format    


  260. WANG F, Demir S, Gehringer F, Osswald CD, et al
    Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
    PubMed     Text format     Abstract available


  261. KRAUSE DS
    Et tu, E2F1? The assassins of CML stem cells.
    Blood. 2018;131:1499-1500.
    PubMed     Text format    


  262. STATLER A, Othus M, Erba HP, Chauncey TR, et al
    Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
    Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
    PubMed     Text format     Abstract available


    March 2018
  263. CORTES JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, et al
    Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086
    PubMed     Text format     Abstract available


  264. PAIETTA E
    Consensus on MRD in AML?
    Blood. 2018;131:1265-1266.
    PubMed     Text format    


  265. SCHUURHUIS GJ, Heuser M, Freeman S, Bene MC, et al
    Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
    Blood. 2018;131:1275-1291.
    PubMed     Text format     Abstract available


  266. WOOD B, Wu D, Crossley B, Dai Y, et al
    Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    Blood. 2018;131:1350-1359.
    PubMed     Text format     Abstract available


  267. RUIZ S, Chen YH
    Acute myeloid leukemia with coexistence of t(9;22) and inv(16).
    Blood. 2018;131:1263.
    PubMed     Text format    


  268. HALLEK M, Cheson BD, Catovsky D, Caligaris-Cappio F, et al
    Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
    Blood. 2018 Mar 14. pii: blood-2017-09-806398. doi: 10.1182/blood-2017-09-806398
    PubMed     Text format     Abstract available


  269. YAMATO G, Shiba N, Yoshida K, Hara Y, et al
    RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
    Blood. 2018 Mar 14. pii: blood-2017-11-814442. doi: 10.1182/blood-2017-11-814442
    PubMed     Text format    


  270. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Text format     Abstract available


  271. SOIFFER RJ, Davids MS, Chen YB
    Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.
    Blood. 2018;131:1073-1080.
    PubMed     Text format     Abstract available


  272. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Text format     Abstract available


  273. SHOMALI W, Gotlib J
    Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
    Blood. 2018;131:1036.
    PubMed     Text format    


  274. WYNNE J, Stock W
    "Dar"-ing to target CD38 in T-ALL.
    Blood. 2018;131:948-949.
    PubMed     Text format    


  275. THOMPSON PA
    MRD negativity as a surrogate for PFS in CLL?
    Blood. 2018;131:943-944.
    PubMed     Text format    


  276. DIMIER N, Delmar P, Ward C, Morariu-Zamfir R, et al
    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
    Blood. 2018;131:955-962.
    PubMed     Text format     Abstract available


    February 2018
  277. KREITMAN RJ, Tallman MS, Robak T, Coutre S, et al
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
    Blood. 2018 Feb 27. pii: blood-2017-09-803072. doi: 10.1182/blood-2017-09-803072
    PubMed     Text format     Abstract available


  278. DUARTE D, Hawkins ED, Lo Celso C
    The interplay of leukemia cells and the bone marrow microenvironment.
    Blood. 2018 Feb 27. pii: blood-2017-12-784132. doi: 10.1182/blood-2017-12-784132
    PubMed     Text format     Abstract available


  279. LIU T, Wen L, Yuan H, Wang Y, et al
    Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Blood. 2018 Feb 27. pii: blood-2017-11-818716. doi: 10.1182/blood-2017-11-818716
    PubMed     Text format    


  280. SCHLIFFKE S, Buhs S, Bolz S, Gerull H, et al
    The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
    Blood. 2018 Feb 23. pii: blood-2017-06-788166. doi: 10.1182/blood-2017-06-788166
    PubMed     Text format    


  281. JAITLY V, Wang W
    B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
    Blood. 2018;131:941.
    PubMed     Text format    


  282. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.
    PubMed     Text format    


  283. GALLIPOLI P, Giotopoulos G, Tzelepis K, Costa ASH, et al
    Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
    Blood. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035
    PubMed     Text format     Abstract available


  284. SCHAFER D, Olsen M, Lahnemann D, Stanulla M, et al
    Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.
    Blood. 2018;131:821-826.
    PubMed     Text format    


  285. CARAFFINI V, Perfler B, Berg JL, Uhl B, et al
    Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
    Blood. 2018;131:826-830.
    PubMed     Text format    


  286. WIERZ M, Pierson S, Guyonnet L, Viry E, et al
    Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
    Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267
    PubMed     Text format    


  287. BHAGWAT AS, Lu B, Vakoc CR
    Enhancer dysfunction in leukemia.
    Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
    PubMed     Text format     Abstract available


  288. NAKADA D
    ENLightening YEATS in antagonizing polycomb repression.
    Blood. 2018;131:591.
    PubMed     Text format    


  289. HETZNER K, Garcia-Cuellar MP, Buttner C, Slany RK, et al
    The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
    Blood. 2018;131:662-673.
    PubMed     Text format     Abstract available


  290. VOISSET E, Moravcsik E, Stratford EW, Jaye A, et al
    Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
    Blood. 2018;131:636-648.
    PubMed     Text format     Abstract available


  291. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
    CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Blood. 2018;131:611-620.
    PubMed     Text format     Abstract available


  292. ZHANG Y, Gao Y, Zhang H, Zhang J, et al
    PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
    Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
    PubMed     Text format     Abstract available


  293. YUN S, Zhang L, Patel MR, Knepper TC, et al
    Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
    Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.
    PubMed     Text format    


  294. MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
    Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
    PubMed     Text format     Abstract available


  295. O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
    Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
    Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
    PubMed     Text format     Abstract available


  296. LAZAREVIC V, Orsmark-Pietras C, Lilljebjorn H, Pettersson L, et al
    Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.
    Blood. 2018;131:577-581.
    PubMed     Text format    


    January 2018
  297. DINMOHAMED AG, Posthuma EFM, Visser O, Kater AP, et al
    Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands.
    Blood. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381
    PubMed     Text format    


  298. SHIMA H, Takamatsu-Ichihara E, Shino M, Yamagata K, et al
    Ring1A and Ring 1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells.
    Blood. 2018 Jan 25. pii: blood-2017-05-787226. doi: 10.1182/blood-2017-05-787226
    PubMed     Text format     Abstract available


  299. TAKAHASHI K, Hu B, Wang F, Yan Y, et al
    Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
    Blood. 2018 Jan 22. pii: blood-2017-11-817296. doi: 10.1182/blood-2017-11-817296
    PubMed     Text format     Abstract available


  300. GOKBUGET N, Dombret H, Bonifacio M, Reichle A, et al
    Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-798322. doi: 10.1182/blood-2017-08-798322
    PubMed     Text format     Abstract available


  301. HANDGRETINGER R, Schilbach K
    The potential role of gammadelta T cells after allogeneic HCT for leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-752162. doi: 10.1182/blood-2017-08-752162
    PubMed     Text format     Abstract available


  302. COOLEY S, Parham P, Miller JS
    Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
    Blood. 2018 Jan 22. pii: blood-2017-08-752170. doi: 10.1182/blood-2017-08-752170
    PubMed     Text format     Abstract available


  303. GUTJAHR JC, Szenes E, Tschech L, Asslaber D, et al
    Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Blood. 2018 Jan 19. pii: blood-2017-08-802462. doi: 10.1182/blood-2017-08-802462
    PubMed     Text format     Abstract available


  304. PFEIFER H, Raum K, Markovic S, Nowak V, et al
    Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
    Blood. 2018 Jan 18. pii: blood-2017-07-796862. doi: 10.1182/blood-2017-07-796862
    PubMed     Text format     Abstract available


  305. SUN W, Triche T Jr., Malvar J, Gaynon P, et al
    A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.
    Blood. 2018 Jan 16. pii: blood-2017-09-803809. doi: 10.1182/blood-2017-09-803809
    PubMed     Text format     Abstract available


  306. JANOVSKA P, Verner J, Kohoutek J, Bryjova L, et al
    Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.
    Blood. 2018 Jan 9. pii: blood-2017-05-786947. doi: 10.1182/blood-2017-05-786947.
    PubMed     Text format     Abstract available


  307. BRIDE KL, Vincent TL, Im SY, Aplenc R, et al
    Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).
    Blood. 2018 Jan 5. pii: blood-2017-07-794214. doi: 10.1182/blood-2017-07-794214.
    PubMed     Text format     Abstract available


  308. COUTRE S, Choi M, Furman RR, Eradat H, et al
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Blood. 2018 Jan 5. pii: blood-2017-06-788133. doi: 10.1182/blood-2017-06-788133.
    PubMed     Text format     Abstract available


  309. LOCKE FL, Anasetti C
    Off-the-shelf TCR for graft-versus-leukemia without GVHD.
    Blood. 2018;131:5-7.
    PubMed     Text format    


  310. MILNE TA
    LEDGF: a leukemia-specific target.
    Blood. 2018;131:4-5.
    PubMed     Text format    


  311. AULETTA JJ
    AML: exposed and exploited?
    Blood. 2018;131:8-10.
    PubMed     Text format    


  312. EL ASHKAR S, Schwaller J, Pieters T, Goossens S, et al
    LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
    Blood. 2018;131:95-107.
    PubMed     Text format     Abstract available


  313. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Text format     Abstract available


    December 2017
  314. GROCKOWIAK E, Laperrousaz B, Jeanpierre S, Voeltzel T, et al
    Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
    Blood. 2017;130:2860-2871.
    PubMed     Text format     Abstract available


  315. SHIOZAWA Y, Malcovati L, Galli A, Pellagatti A, et al
    Gene expression and risk of leukemic transformation in myelodysplasia.
    Blood. 2017;130:2642-2653.
    PubMed     Text format     Abstract available


  316. PRATS-MARTIN C, Morales-Camacho RM
    Circulating hypergranular neoplastic cells: not always leukemic promyelocytes.
    Blood. 2017;130:2689.
    PubMed     Text format    


  317. YAO L, Wen L, Wang N, Liu T, et al
    Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA.
    Blood. 2017 Dec 13. pii: blood-2017-09-807370. doi: 10.1182/blood-2017-09-807370
    PubMed     Text format    


  318. RAIKAR SS, Park SI, Leong T, Jaye DL, et al
    Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
    Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.
    PubMed     Text format    


  319. WEI AH, Tiong IS
    Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Blood. 2017;130:2469-2474.
    PubMed     Text format     Abstract available


  320. BOSE P, Konopleva MY
    T-PLL: another check on the venetoclax list?
    Blood. 2017;130:2447-2448.
    PubMed     Text format    


  321. OBSTFELD AE, Frey NV, Mansfield K, Lacey SF, et al
    Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
    Blood. 2017;130:2569-2572.
    PubMed     Text format    


  322. STEIN EM, Walter RB, Erba HP, Fathi AT, et al
    A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML).
    Blood. 2017 Dec 1. pii: blood-2017-06-789800. doi: 10.1182/blood-2017-06-789800.
    PubMed     Text format     Abstract available


    November 2017
  323. COOPER JN, Young NS
    Clonality in context: hematopoietic clones in their marrow environment.
    Blood. 2017;130:2363-2372.
    PubMed     Text format     Abstract available


  324. ZHEN T, Kwon EM, Zhao L, Hsu J, et al
    Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.
    Blood. 2017;130:2431-2442.
    PubMed     Text format     Abstract available


  325. RASHIDI A, Gilles S
    The unused iron.
    Blood. 2017;130:2445.
    PubMed     Text format    


  326. STRAUBE J, Ling VY, Hill GR, Lane SW, et al
    The impact of age, NPM1(mut) and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia.
    Blood. 2017 Nov 28. pii: blood-2017-09-807438. doi: 10.1182/blood-2017-09-807438
    PubMed     Text format    


  327. JOHNSRUD AJ, Pina-Oviedo S
    Carcinocythemia (carcinoma cell leukemia).
    Blood. 2017;130:2357.
    PubMed     Text format    


  328. CHAI-ADISAKSOPHA C, Brown JR
    FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
    Blood. 2017;130:2278-2282.
    PubMed     Text format     Abstract available


  329. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  330. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  331. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  332. HU Z, Konoplev S
    Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia.
    Blood. 2017;130:2150.
    PubMed     Text format    


  333. ISSA GC, Kantarjian HM, Gonzalez GN, Borthakur G, et al
    Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
    Blood. 2017;130:2084-2091.
    PubMed     Text format     Abstract available


  334. HEHLMANN R
    Prognostic relevance of CCAs/Ph(-) in CML settled.
    Blood. 2017;130:2046-2047.
    PubMed     Text format    


  335. LOCATELLI F, Valsecchi MG, Moricke A, Zimmermann M, et al
    Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
    Blood. 2017;130:2146-2149.
    PubMed     Text format    


  336. SERAFIN V, Capuzzo G, Milani G, Minuzzo SA, et al
    Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2017 Nov 3. pii: blood-2017-05-784603. doi: 10.1182/blood-2017-05-784603.
    PubMed     Text format     Abstract available


  337. TAWARA I, Kageyama S, Miyahara Y, Fujiwara H, et al
    Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
    Blood. 2017;130:1985-1994.
    PubMed     Text format     Abstract available


    October 2017
  338. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI): a systematic review and meta-analysis.
    Blood. 2017 Oct 30. pii: blood-2017-09-806034. doi: 10.1182/blood-2017-09-806034
    PubMed     Text format    


  339. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  340. FALINI B, Sportoletti P
    A scale of "bad" co-mutations in NPM1-driven AML.
    Blood. 2017;130:1877-1879.
    PubMed     Text format    


  341. BOUVIER S, Martin M
    Atypical monoblasts with micronuclei.
    Blood. 2017;130:1958.
    PubMed     Text format    


  342. GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
    AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
    Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
    PubMed     Text format     Abstract available


  343. DOSSA RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, et al
    Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
    Blood. 2017 Oct 19. pii: blood-2017-07-791608. doi: 10.1182/blood-2017-07-791608
    PubMed     Text format     Abstract available


  344. PETIT A, Trinquand A, Chevret S, Ballerini P, et al
    Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-04-778829. doi: 10.1182/blood-2017-04-778829
    PubMed     Text format     Abstract available


  345. TIAO G, Improgo MR, Tausch E, Fernandes SM, et al
    Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128
    PubMed     Text format    


  346. HARANKHEDKAR S, Gupta R
    MPO-negative inclusions and Auer rod-like structures in a case of acute myeloid leukemia with t(8;21).
    Blood. 2017;130:1869.
    PubMed     Text format    


  347. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  348. ODA SK, Daman AW, Garcia NM, Wagener F, et al
    A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.
    Blood. 2017 Oct 17. pii: blood-2017-04-777052. doi: 10.1182/blood-2017-04-777052
    PubMed     Text format     Abstract available


  349. SANDA T
    RUNX1 in T-ALL: tumor suppressive or oncogenic?
    Blood. 2017;130:1686-1688.
    PubMed     Text format    


  350. XU Z
    AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis.
    Blood. 2017;130:1775.
    PubMed     Text format    


  351. APPELBAUM FR, Bernstein ID
    Gemtuzumab ozogamicin for acute myeloid leukemia.
    Blood. 2017 Oct 11. pii: blood-2017-09-797712. doi: 10.1182/blood-2017-09-797712
    PubMed     Text format     Abstract available


  352. MAR BG, Chu SH, Kahn JD, Krivstov AV, et al
    SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
    Blood. 2017 Oct 10. pii: blood-2017-03-775569. doi: 10.1182/blood-2017-03-775569
    PubMed     Text format     Abstract available


  353. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017;130:1620-1627.
    PubMed     Text format     Abstract available


  354. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  355. MARLEIN CR, Zaitseva L, Piddock RE, Robinson SD, et al
    NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.
    Blood. 2017;130:1649-1660.
    PubMed     Text format     Abstract available


  356. WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
    PubMed     Text format     Abstract available


  357. TASIAN SK, Loh ML, Hunger SP
    Philadelphia chromosome-like acute lymphoblastic leukemia.
    Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
    PubMed     Text format     Abstract available


    September 2017
  358. THAKRAL B, Wang SA
    "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood. 2017;130:1600.
    PubMed     Text format    


  359. KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
    Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Blood. 2017;130:1585-1596.
    PubMed     Text format     Abstract available


  360. JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
    Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Blood. 2017;130:1514-1522.
    PubMed     Text format     Abstract available


  361. ADVANI AS
    "MOR" engineering of antibodies in ALL.
    Blood. 2017;130:1487-1488.
    PubMed     Text format    


  362. BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
    First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
    PubMed     Text format     Abstract available


  363. MUELLER KT, Maude SL, Porter DL, Frey N, et al
    Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
    PubMed     Text format     Abstract available


  364. SHEA TC
    Are outcomes of allografts for CLL still relevant?
    Blood. 2017;130:1393-1394.
    PubMed     Text format    


  365. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  366. KRAMER I, Stilgenbauer S, Dietrich S, Bottcher S, et al
    Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
    Blood. 2017;130:1477-1480.
    PubMed     Text format    


  367. ZURLI V, Wimmer G, Cattaneo F, Candi V, et al
    Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
    Blood. 2017 Sep 20. pii: blood-2017-03-775858. doi: 10.1182/blood-2017-03-775858
    PubMed     Text format     Abstract available


  368. WANG HY, Feldman AL
    Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia.
    Blood. 2017;130:1387.
    PubMed     Text format    


  369. LIN S, Ptasinska A, Chen X, Shrestha M, et al
    A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Blood. 2017;130:1213-1222.
    PubMed     Text format     Abstract available


  370. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  371. AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
    A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
    Blood. 2017;130:1270-1273.
    PubMed     Text format    


    August 2017
  372. BAZARBACHI A
    CDK9 inhibition for ATL therapy.
    Blood. 2017;130:1074-1075.
    PubMed     Text format    


  373. LEHNERTZ B, Zhang YW, Boivin I, Mayotte N, et al
    H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.
    Blood. 2017 Aug 30. pii: blood-2017-03-774653. doi: 10.1182/blood-2017-03-774653
    PubMed     Text format     Abstract available


  374. DOVEY OM, Cooper JL, Mupo A, Grove CS, et al
    Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.
    Blood. 2017 Aug 23. pii: blood-2017-01-760595. doi: 10.1182/blood-2017-01-760595
    PubMed     Text format     Abstract available


  375. BRUNSON A, Keegan THM, Bang H, Mahajan A, et al
    Increased risk of leukemia among sickle cell disease patients in California.
    Blood. 2017 Aug 22. pii: blood-2017-05-783233. doi: 10.1182/blood-2017-05-783233
    PubMed     Text format    


  376. ANGUILLE S, Van de Velde AL, Smits EL, Van Tendeloo VF, et al
    Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia.
    Blood. 2017 Aug 22. pii: blood-2017-04-780155. doi: 10.1182/blood-2017-04-780155
    PubMed     Text format     Abstract available


  377. NAGEL I, Bartels M, Duell J, Oberg HH, et al
    Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.
    Blood. 2017 Aug 21. pii: blood-2017-05-782888. doi: 10.1182/blood-2017-05-782888
    PubMed     Text format     Abstract available


  378. ZHOU XY, Behdad A
    Relapse of an acute leukemia of mixed lineage as an isolated orbital mass.
    Blood. 2017;130:953.
    PubMed     Text format    


  379. KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
    GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Blood. 2017;130:908-919.
    PubMed     Text format     Abstract available


  380. MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
    Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Blood. 2017;130:946-948.
    PubMed     Text format    


  381. DURHAM BH, Getta B, Dietrich S, Taylor J, et al
    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
    Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
    PubMed     Text format     Abstract available


  382. KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
    JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Blood. 2017;130:789-802.
    PubMed     Text format     Abstract available


  383. WOUTERS BJ
    Hitting the target in IDH2 mutant AML.
    Blood. 2017;130:693-694.
    PubMed     Text format    


  384. SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
    Blood. 2017;130:832-835.
    PubMed     Text format    


  385. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017 Aug 9. pii: blood-2017-02-749101. doi: 10.1182/blood-2017-02-749101.
    PubMed     Text format     Abstract available


  386. CHOI A, Illendula A, Pulikkan JA, Roderick JE, et al
    RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-03-775536. doi: 10.1182/blood-2017-03-775536.
    PubMed     Text format     Abstract available


  387. LAFAGE-POCHITALOFF M, Baranger L, Hunault M, Cuccuini W, et al
    Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-05-783852. doi: 10.1182/blood-2017-05-783852.
    PubMed     Text format     Abstract available


  388. MIZUKAWA B, O'Brien E, Moreira DC, Wunderlich M, et al
    Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
    Blood. 2017 Aug 4. pii: blood-2016-12-758458. doi: 10.1182/blood-2016-12-758458.
    PubMed     Text format     Abstract available


  389. LILLJEBJORN H, Fioretos T
    New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 4. pii: blood-2017-05-742643. doi: 10.1182/blood-2017-05-742643.
    PubMed     Text format     Abstract available


  390. ARRANTO C, Tzankov A
    Broken heart by T-prolymphocytic leukemia.
    Blood. 2017;130:691.
    PubMed     Text format    


  391. IZRAELI S, Eckert C
    Targeted therapy of CNS leukemia?
    Blood. 2017;130:562-563.
    PubMed     Text format    


  392. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  393. WALLACE JA, O'Connell RM
    MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
    Blood. 2017 Jul 27. pii: blood-2016-10-697698. doi: 10.1182/blood-2016-10-697698
    PubMed     Text format     Abstract available


  394. GODLEY LA, Shimamura A
    Genetic predisposition to hematologic malignancies: management and surveillance.
    Blood. 2017;130:424-432.
    PubMed     Text format     Abstract available


  395. YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Blood. 2017;130:397-407.
    PubMed     Text format     Abstract available


  396. RAU RE
    CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3.
    Blood. 2017;130:385-386.
    PubMed     Text format    


  397. DONG L, Zheng H, Qu CK
    CCL3 is a key mediator for the leukemogenic effect of Ptpn11 activating mutations in the stem cell microenvironment.
    Blood. 2017 Jul 27. pii: blood-2017-06-791103. doi: 10.1182/blood-2017-06-791103
    PubMed     Text format    


  398. TOBOSO DG, Campos CB
    Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32).
    Blood. 2017;130:380.
    PubMed     Text format    


  399. GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Blood. 2017;130:285-296.
    PubMed     Text format     Abstract available


  400. AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
    CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Blood. 2017;130:297-309.
    PubMed     Text format     Abstract available



  401. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood. 2017;130:232.
    PubMed     Text format    


  402. THAKRAL B, Muzzafar T
    Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Blood. 2017;130:231.
    PubMed     Text format    


  403. TALSMA CE, Boyer DF
    Myeloid leukemia associated with Down syndrome.
    Blood. 2017;130:230.
    PubMed     Text format    


  404. AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
    USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood. 2017;130:156-166.
    PubMed     Text format     Abstract available


  405. SAMPATH D
    Targeting deubiquitinases in CLL.
    Blood. 2017;130:100-101.
    PubMed     Text format    


  406. PILLAI V, Maude SL
    CART attack.
    Blood. 2017;130:229.
    PubMed     Text format    


  407. SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
    An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
    Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
    PubMed     Text format     Abstract available


  408. CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
    Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
    Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121
    PubMed     Text format    


  409. BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
    Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
    Blood. 2017;130:86-88.
    PubMed     Text format    


  410. KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
    HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
    Blood. 2017;130:84-86.
    PubMed     Text format    


    June 2017
  411. QUESADA AE, Kanagal-Shamanna R
    Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
    Blood. 2017;129:3503.
    PubMed     Text format    


  412. LEVIS M
    Midostaurin approved for FLT3-mutated AML.
    Blood. 2017;129:3403-3406.
    PubMed     Text format     Abstract available


  413. CHAUDHRY P, Singh M, Triche TJ, Guzman M, et al
    GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
    Blood. 2017;129:3465-3475.
    PubMed     Text format     Abstract available


  414. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  415. RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
    In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
    Blood. 2017;129:3495-3498.
    PubMed     Text format    


  416. MORIYAMA T, Yang YL, Nishii R, Ariffin H, et al
    Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
    Blood. 2017 Jun 28. pii: blood-2017-05-782383. doi: 10.1182/blood-2017-05-782383
    PubMed     Text format     Abstract available


  417. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  418. BRIERLEY CK, Eyre TA
    Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
    Blood. 2017;129:3396.
    PubMed     Text format    


  419. ANDERSON MA, Tam C, Lew TE, Juneja S, et al
    Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
    Blood. 2017;129:3362-3370.
    PubMed     Text format     Abstract available


  420. MALCOVATI L, Galli A, Travaglino E, Ambaglio I, et al
    Clinical significance of somatic mutation in unexplained blood cytopenia.
    Blood. 2017;129:3371-3378.
    PubMed     Text format     Abstract available


  421. RESHMI SC, Harvey RC, Roberts KG, Stonerock E, et al
    Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Blood. 2017;129:3352-3361.
    PubMed     Text format     Abstract available


  422. TOMIZAWA D, Kolb EA
    Down syndrome and AML: where do we go from here?
    Blood. 2017;129:3274-3275.
    PubMed     Text format    


  423. SHAND JC
    Looking up for AML in Down syndrome.
    Blood. 2017;129:3273-3274.
    PubMed     Text format    


  424. GRIBBEN JG
    Restoring leukemia cell function from the inside out.
    Blood. 2017;129:3137-3138.
    PubMed     Text format    


  425. GOOSSENS S, Van Vlierberghe P
    Novel oncogenic noncoding mutations in T-ALL.
    Blood. 2017;129:3140-3142.
    PubMed     Text format    


  426. GARRISON BS, Rybak AP, Beerman I, Heesters B, et al
    ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
    Blood. 2017 Jun 14. pii: blood-2016-09-738591. doi: 10.1182/blood-2016-09-738591
    PubMed     Text format     Abstract available


  427. PROKOCIMER M, Molchadsky A, Rotter V
    Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy.
    Blood. 2017 Jun 12. pii: blood-2017-02-763086. doi: 10.1182/blood-2017-02-763086
    PubMed     Text format     Abstract available


  428. PRIETO D, Sotelo N, Seija N, Sernbo S, et al
    S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-kappaB activity during disease progression.
    Blood. 2017 Jun 8. pii: blood-2017-02-769851. doi: 10.1182/blood-2017-02-769851.
    PubMed     Text format     Abstract available


  429. WALLACE JA, Kagele DA, Eiring AM, Kim CN, et al
    miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Blood. 2017;129:3074-3086.
    PubMed     Text format     Abstract available


  430. RASHIDI A, Courville EL
    Double-heart sign.
    Blood. 2017;129:3134.
    PubMed     Text format    


  431. KATO I, Nishinaka Y, Nakamura M, Akarca AU, et al
    Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.
    Blood. 2017;129:3126-3129.
    PubMed     Text format    


  432. STEIN EM, DiNardo CD, Pollyea DA, Fathi AT, et al
    Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.
    Blood. 2017 Jun 6. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.
    PubMed     Text format     Abstract available


  433. AMATANGELO MD, Quek L, Shih A, Stein EM, et al
    Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Blood. 2017 Jun 6. pii: blood-2017-04-779447. doi: 10.1182/blood-2017-04-779447.
    PubMed     Text format     Abstract available


  434. LOCATELLI F, Merli P, Pagliara D, Li Pira G, et al
    Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion.
    Blood. 2017 Jun 6. pii: blood-2017-04-779769. doi: 10.1182/blood-2017-04-779769.
    PubMed     Text format     Abstract available


  435. CHELONI G, Tanturli M, Tusa I, DeSouza NH, et al
    Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
    Blood. 2017 Jun 2. pii: blood-2016-10-745588. doi: 10.1182/blood-2016-10-745588.
    PubMed     Text format     Abstract available


  436. SOLARY E, Itzykson R
    How I treat chronic myelomonocytic leukemia.
    Blood. 2017 Jun 1. pii: blood-2017-04-736421. doi: 10.1182/blood-2017-04-736421.
    PubMed     Text format     Abstract available


    May 2017
  437. MUNCH V, Trentin L, Herzig J, Demir S, et al
    Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor.
    Blood. 2017 May 26. pii: blood-2017-03-769315. doi: 10.1182/blood-2017-03-769315
    PubMed     Text format     Abstract available


  438. MAN N, Tan Y, Sun XJ, Liu F, et al
    Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
    Blood. 2017;129:2782-2792.
    PubMed     Text format     Abstract available


  439. HOVORKOVA L, Zaliova M, Venn NC, Bleckmann K, et al
    Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
    Blood. 2017;129:2771-2781.
    PubMed     Text format     Abstract available


  440. HUNGER SP
    CML in blast crisis: more common than we think?
    Blood. 2017;129:2713-2714.
    PubMed     Text format    


  441. WALTER HS, Jayne S, Rule SA, Cartron G, et al
    Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
    Blood. 2017;129:2808-2810.
    PubMed     Text format    


  442. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  443. CHEN TL, Tran M, Lakshmanan A, Harrington BK, et al
    NF-kappaB p50 (nfkb1) contributes to pathogenesis in the Emu-TCL1 mouse model of chronic lymphocytic leukemia.
    Blood. 2017 May 17. pii: blood-2017-01-761130. doi: 10.1182/blood-2017-01-761130
    PubMed     Text format    


  444. BARR PM, Brown JR, Hillmen P, O'Brien S, et al
    Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood. 2017;129:2612-2615.
    PubMed     Text format     Abstract available


  445. VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
    Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Blood. 2017;129:2636-2644.
    PubMed     Text format     Abstract available


  446. LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
    Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
    Blood. 2017;129:2657-2666.
    PubMed     Text format     Abstract available


  447. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  448. PINTON P
    A mitochondrial drug to treat AML.
    Blood. 2017;129:2597-2599.
    PubMed     Text format    


  449. SMITH CC, Paguirigan A, Jeschke GR, Lin KC, et al
    Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis.
    Blood. 2017 May 10. pii: blood-2016-04-711820. doi: 10.1182/blood-2016-04-711820
    PubMed     Text format     Abstract available


  450. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  451. DOURADO KMC, Baik J, Oliveira VKP, Beltrame M, et al
    Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
    Blood. 2017;129:2526-2536.
    PubMed     Text format     Abstract available


  452. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  453. LAMPSON BL, Yu L, Glynn RJ, Barrientos JC, et al
    Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Blood. 2017;129:2581-2584.
    PubMed     Text format    


  454. GORINI F, Azzimonti L, Delfanti G, Scarfo L, et al
    Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
    Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
    PubMed     Text format     Abstract available


    April 2017
  455. PARILLA M, Venkataraman G
    The thin line between CML and CMML.
    Blood. 2017;129:2456.
    PubMed     Text format    


  456. RADICH J
    Understanding CML, 1 cell at a time.
    Blood. 2017;129:2339-2340.
    PubMed     Text format    


  457. KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
    Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
    PubMed     Text format     Abstract available


  458. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  459. VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
    Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
    PubMed     Text format     Abstract available


  460. GARDNER RA, Finney O, Annesley C, Brakke H, et al
    Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
    Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
    PubMed     Text format     Abstract available


  461. HU S, Qian M, Zhang H, Guo Y, et al
    Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
    Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162
    PubMed     Text format    



  462. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
    Blood. 2017;129:2204.
    PubMed     Text format    


  463. PORCHER C, Chagraoui H, Kristiansen MS
    SCL/TAL1: a multifaceted regulator from blood development to disease.
    Blood. 2017;129:2051-2060.
    PubMed     Text format     Abstract available


  464. SOOD R, Kamikubo Y, Liu P
    Role of RUNX1 in hematological malignancies.
    Blood. 2017;129:2070-2082.
    PubMed     Text format     Abstract available


  465. AVELLINO R, Delwel R
    Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation.
    Blood. 2017;129:2083-2091.
    PubMed     Text format     Abstract available


  466. DE BRUIJN M, Dzierzak E
    Runx transcription factors in the development and function of the definitive hematopoietic system.
    Blood. 2017;129:2061-2069.
    PubMed     Text format     Abstract available


  467. UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
    Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
    Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
    PubMed     Text format     Abstract available


  468. BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
    Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
    PubMed     Text format     Abstract available


  469. TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
    Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
    PubMed     Text format     Abstract available


  470. LANDIER W, Chen Y, Hageman L, Kim H, et al
    Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
    Blood. 2017;129:1919-1926.
    PubMed     Text format     Abstract available


  471. DOWSE RT, Ireland RM
    Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL.
    Blood. 2017;129:2038.
    PubMed     Text format    


    March 2017
  472. GO RS, Winters JL, Kay NE
    How I treat autoimmune hemolytic anemia.
    Blood. 2017 Mar 30. pii: blood-2016-11-693689. doi: 10.1182/blood-2016-11-693689
    PubMed     Text format     Abstract available


  473. GREENBERG PL
    The classical nature of distinctive CMML monocytes.
    Blood. 2017;129:1745-1746.
    PubMed     Text format    


  474. FALANGA A
    Predicting APL lethal bleeding in the ATRA era.
    Blood. 2017;129:1739-1740.
    PubMed     Text format    


  475. TALATI C, Zhang L, Shaheen G, Kuykendall A, et al
    Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
    Blood. 2017;129:1881-1883.
    PubMed     Text format    


  476. GEYER MB, Hsu M, Devlin SM, Tallman MS, et al
    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
    Blood. 2017;129:1878-1881.
    PubMed     Text format    


  477. BACHEGOWDA LS, Saliba RM, Ramlal R, Kongtim P, et al
    Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.
    Blood. 2017 Mar 28. pii: blood-2017-02-766154. doi: 10.1182/blood-2017-02-766154
    PubMed     Text format    


  478. GARZON R, Savona M, Baz R, Andreeff M, et al
    A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
    PubMed     Text format     Abstract available


  479. FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973
    PubMed     Text format    


  480. CHENG CK, Wang AZ, Wong TH, Wan TS, et al
    FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
    Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707
    PubMed     Text format    


  481. FRISMANTAS V, Dobay MP, Rinaldi A, Tchinda J, et al
    Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Blood. 2017;129:e26-e37.
    PubMed     Text format     Abstract available


  482. WONG TN, Link DC
    miR-125b promotes leukemogenesis via VEGFA.
    Blood. 2017;129:1409-1410.
    PubMed     Text format    


  483. MERTENS D, Stilgenbauer S
    Ibrutinib-resistant CLL: unwanted and unwonted!
    Blood. 2017;129:1407-1409.
    PubMed     Text format    


  484. SHAFAT MS, Oellerich T, Mohr S, Robinson SD, et al
    Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
    Blood. 2017;129:1320-1332.
    PubMed     Text format     Abstract available


  485. SCHURINGA JJ
    Smart niche usage: release its fat and burn it!
    Blood. 2017;129:1239-1240.
    PubMed     Text format    


  486. DUNCAVAGE EJ, Uy GL, Petti AA, Miller CA, et al
    Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
    Blood. 2017;129:1397-1401.
    PubMed     Text format    


  487. GIRARDI T, Vicente C, Cools J, De Keersmaecker K, et al
    The genetics and molecular biology of T-ALL.
    Blood. 2017;129:1113-1123.
    PubMed     Text format     Abstract available


  488. HUGHES A, Clarson J, Tang C, Vidovic L, et al
    CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Blood. 2017;129:1166-1176.
    PubMed     Text format     Abstract available


  489. KNAPPER S, Russell N, Gilkes A, Hills RK, et al
    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Blood. 2017;129:1143-1154.
    PubMed     Text format     Abstract available


  490. SCHEINBERG DA
    Immune reconstitution and remission in CML.
    Blood. 2017;129:1064-1065.
    PubMed     Text format    


  491. STONE RM
    3 + 7 + FLT3 inhibitors: 1 + 1 not equal 2.
    Blood. 2017;129:1061-1062.
    PubMed     Text format    


  492. ALDOSS I, Song JY
    Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
    Blood. 2017;129:1231.
    PubMed     Text format    


  493. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


  494. LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
    Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
    Blood. 2017;129:1227-1230.
    PubMed     Text format    


    February 2017
  495. AGARWAL P, Zhang B, Ho Y, Cook A, et al
    Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Blood. 2017;129:1008-1020.
    PubMed     Text format     Abstract available


  496. KORN C, Mendez-Ferrer S
    Myeloid malignancies and the microenvironment.
    Blood. 2017;129:811-822.
    PubMed     Text format     Abstract available


  497. LANEUVILLE P
    Stopping second-generation TKIs in CML.
    Blood. 2017;129:805-806.
    PubMed     Text format    


  498. POURABDOLLAH M, Chang H
    Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
    Blood. 2017;129:918.
    PubMed     Text format    


  499. REITER A, Gotlib J
    Myeloid neoplasms with eosinophilia.
    Blood. 2017;129:704-714.
    PubMed     Text format     Abstract available


  500. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


  501. ALSULIMAN A, Muftuoglu M, Khoder A, Ahn YO, et al
    A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
    Blood. 2017;129:740-758.
    PubMed     Text format     Abstract available


  502. LOWENBERG B
    Introduction to the Review Series on Leukemic Stem Cells.
    Blood. 2017 Feb 3. pii: blood-2017-01-753319. doi: 10.1182/blood-2017-01-753319.
    PubMed     Text format    


  503. COMOLI P, Basso S, Riva G, Barozzi P, et al
    BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
    Blood. 2017;129:582-586.
    PubMed     Text format     Abstract available


  504. PRATZ KW, Levis M
    How I treat FLT3-mutated AML.
    Blood. 2017;129:565-571.
    PubMed     Text format     Abstract available


  505. LULLA P, Heslop HE
    Fall of the mutants: T cells targeting BCR-ABL.
    Blood. 2017;129:539-540.
    PubMed     Text format    


    January 2017
  506. DOHNER H, Estey E, Grimwade D, Amadori S, et al
    Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Blood. 2017;129:424-447.
    PubMed     Text format     Abstract available


  507. CHESNAIS V, Arcangeli ML, Delette C, Rousseau A, et al
    Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Blood. 2017;129:484-496.
    PubMed     Text format     Abstract available


  508. WARFVINGE R, Geironson Ulfsson L, Sommarin MN, Lang S, et al
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Blood. 2017 Jan 25. pii: blood-2016-07-728873. doi: 10.1182/blood-2016-07-728873
    PubMed     Text format     Abstract available


  509. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  510. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.
    PubMed     Text format    


  511. VAINCHENKER W, Plo I
    P53 deletion and NrasG12D cooperate for AML.
    Blood. 2017;129:271-273.
    PubMed     Text format    


  512. ASKEW D, Pareek TK, Eid S, Ganguly S, et al
    Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Blood. 2017;129:246-256.
    PubMed     Text format     Abstract available


  513. ABU ZAID M, Wu J, Wu C, Logan BR, et al
    Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
    Blood. 2017;129:162-170.
    PubMed     Text format     Abstract available


  514. TARAFDAR A, Hopcroft LE, Gallipoli P, Pellicano F, et al
    CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
    Blood. 2017;129:199-208.
    PubMed     Text format     Abstract available


  515. NICOLINI FE
    CML stem cells: evasion for better invasion.
    Blood. 2017;129:141-142.
    PubMed     Text format    


  516. LEE LY, Hernandez D, Rajkhowa T, Smith SC, et al
    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
    Blood. 2017;129:257-260.
    PubMed     Text format    


  517. WALTER MJ
    Antecedent CHIP in CML?
    Blood. 2017;129:3-4.
    PubMed     Text format    


    December 2016
  518. STRAMUCCI L, Perrotti D
    Twisting IL-1 signaling to kill CML stem cells.
    Blood. 2016;128:2592-2593.
    PubMed     Text format    


    November 2016
  519. WILLIAMS KM
    How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Blood. 2016 Nov 16. pii: blood-2016-08-693507.
    PubMed     Text format     Abstract available


  520. CUSAN M, Vegi NM, Mulaw MA, Bamezai S, et al
    Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.
    Blood. 2016 Nov 8. pii: blood-2016-04-706978.
    PubMed     Text format     Abstract available


  521. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.
    PubMed     Text format    


    August 2016
  522. COOMBS J, Bera E
    B cells mimicking blasts after an allogeneic stem cell transplantation.
    Blood. 2016;128:881.
    PubMed     Text format    


    February 2016
  523. TEIRA P, Battiwalla M, Ramanathan M, Barrett AJ, et al
    Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis.
    Blood. 2016 Feb 16. pii: blood-2015-11-679639.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: